CAS NO: | 632-85-9 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Molecular Weight (MW) | 284.26 |
---|---|
Formula | C16H12O5 |
CAS No. | 632-85-9 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 56 mg/mL (197.0 mM) |
Water: <1 mg/mL | |
Ethanol: 8 mg/mL (28.1 mM) | |
Other info | Chemical Name: 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl- InChi Key: XLTFNNCXVBYBSX-UHFFFAOYSA-N InChi Code: InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3 SMILES Code: O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13 |
Synonyms | Vogonin |
In Vitro | In vitro activity: Wogonin induced a G1 phase cell cycle arrest in HCT116 cells in a concentration- and time-dependent manner. Meanwhile, the cell cycle-related proteins, such as cyclin A, E, D1, and CDK2, 4 were down-regulated in wogonin-induced G1 cell cycle arrest. Furthermore, we showed that the anti-proliferation and G1 arrest effect of wogonin on HCT116 cells was associated with deregulation of Wnt/β-catenin signaling pathway. Wogonin could potently promote Aβ clearance in the primary neural astrocytes and significantly decrease Aβ secretion in SH-SY5Y-APP and BACE1 cells through the mTOR/autophagy signaling pathway. wogonin not only inhibited the expression and interaction of TLR4, MyD88, and TAK1, but also reduced the activation of nuclear factor kappa B and mitogen-activated protein kinases pathway in LPS-treated DRG neurons. Moreover, wogonin significantly suppressed the release of pro-inflammatory mediators in LPS-induced DRG neurons, including cyclooxygenase-2, inducible nitric oxide synthases, interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha. Wogonin up-regulated transcription factor GATA-1 and enhanced binding between GATA-1 and FOG-1, thereby increasing expression of erythroid-differentiation genes. Wogonin also up-regulated the expression of p21 and induced cell cycle arrest. |
---|---|
In Vivo | Treatment with Wogonin reduced CLP-induced release of HMGB1 and sepsis-related mortality and pulmonary injury in mice. In vivo results indicated that wogonin attenuated LPS-induced histological alterations. Peripheral blood leucocytes decreased in the LPS-induced group, which was ameliorated by wogonin. In addition, wogonin inhibited the production of several inflammatory cytokines, including tumour necrosis factor-α, interleukin-1β (IL-1β) and IL-6. |
Animal model | Mice |
Formulation & Dosage | N/A |
References | Toxicology. 2013 Oct 4;312:36-47; Neurol Sci. 2015 Jul;36(7):1181-8; Toxicol Appl Pharmacol. 2014 Nov 15;281(1):30-8; Oncotarget. 2014 Sep 30;5(18):8188-201; Immunology. 2014 Oct;143(2):241-57. |